| Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE‐AF consortium A Alonso, BP Krijthe, T Aspelund, KA Stepas, MJ Pencina, CB Moser, ... Journal of the American Heart Association 2 (2), e000102, 2013 | 793 | 2013 |
| B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies MF Sinner, KA Stepas, CB Moser, BP Krijthe, T Aspelund, N Sotoodehnia, ... Europace 16 (10), 1426-1433, 2014 | 197 | 2014 |
| Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s GA McComsey, C Moser, J Currier, HJ Ribaudo, P Paczuski, MP Dubé, ... Clinical Infectious Diseases 62 (7), 853-862, 2016 | 162 | 2016 |
| Risk assessment for incident heart failure in individuals with atrial fibrillation RB Schnabel, M Rienstra, LM Sullivan, JX Sun, CB Moser, D Levy, ... European journal of heart failure 15 (8), 843-849, 2013 | 138 | 2013 |
| Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or … TT Brown, C Moser, JS Currier, HJ Ribaudo, J Rothenberg, T Kelesidis, ... The Journal of infectious diseases 212 (8), 1241-1249, 2015 | 135 | 2015 |
| Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial BO Taiwo, VC Marconi, B Berzins, CB Moser, AN Nyaku, CJ Fichtenbaum, ... Clinical Infectious Diseases 66 (11), 1794-1797, 2018 | 124 | 2018 |
| Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s T Kelesidis, TTT Tran, JH Stein, TT Brown, C Moser, HJ Ribaudo, ... Clinical Infectious Diseases 61 (4), 651-660, 2015 | 120 | 2015 |
| Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart Study JW Magnani, CB Moser, JM Murabito, LM Sullivan, N Wang, PT Ellinor, ... Circulation: Arrhythmia and Electrophysiology 7 (2), 307-312, 2014 | 107 | 2014 |
| Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community SA Lubitz, C Moser, L Sullivan, M Rienstra, JD Fontes, ML Villalon, M Pai, ... Journal of the American Heart Association 2 (5), e000126, 2013 | 93 | 2013 |
| Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race P Bhagwat, I Ofotokun, GA McComsey, TT Brown, C Moser, CA Sugar, ... Open forum infectious diseases 5 (11), ofy201, 2018 | 75 | 2018 |
| Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial SE Krown, CB Moser, P MacPhail, RM Matining, C Godfrey, SR Caruso, ... The Lancet 395 (10231), 1195-1207, 2020 | 69 | 2020 |
| Soluble urokinase plasminogen activator receptor is predictive of non-AIDS events during antiretroviral therapy–mediated viral suppression M Hoenigl, CB Moser, N Funderburg, R Bosch, A Kantor, Y Zhang, ... Clinical Infectious Diseases 69 (4), 676-686, 2019 | 61 | 2019 |
| Changes in insulin resistance after initiation of raltegravir or protease inhibitors with tenofovir-emtricitabine: AIDS Clinical Trials Group A5260s S Dirajlal-Fargo, C Moser, TT Brown, T Kelesidis, MP Dube, JH Stein, ... Open forum infectious diseases 3 (3), ofw174, 2016 | 49 | 2016 |
| Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 KW Chew, C Moser, ES Daar, DA Wohl, JZ Li, RW Coombs, J Ritz, ... Nature communications 13 (1), 4931, 2022 | 39 | 2022 |
| Age of natural menopause and atrial fibrillation: the Framingham Heart Study JW Magnani, CB Moser, JM Murabito, KP Nelson, JD Fontes, SA Lubitz, ... American heart journal 163 (4), 729-734, 2012 | 39 | 2012 |
| Randomized trial of ruxolitinib in antiretroviral-treated adults with human immunodeficiency virus VC Marconi, C Moser, C Gavegnano, SG Deeks, MM Lederman, ... Clinical Infectious Diseases 74 (1), 95-104, 2022 | 30 | 2022 |
| Lower pretreatment gut integrity is independently associated with fat gain on antiretroviral therapy V El Kamari, C Moser, CO Hileman, JS Currier, TT Brown, L Johnston, ... Clinical Infectious Diseases 68 (8), 1394-1401, 2019 | 29 | 2019 |
| Statistical estimation of the reproductive number from case notification data LF White, CB Moser, RN Thompson, M Pagano American Journal of Epidemiology 190 (4), 611-620, 2021 | 26 | 2021 |
| Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events S Gianella, C Moser, A Vitomirov, A McKhann, L Layman, B Scott, ... Aids 34 (6), 849-857, 2020 | 25 | 2020 |
| Predictors of severe weight/body mass index gain following antiretroviral initiation P Bhagwat, I Ofotokun, GA McComsey, T Brown, C Moser, CA Sugar Poster presented at Conference on Retroviruses and Opportunistic Infections, 2017 | 24 | 2017 |
